Petrakopoulou Paraskevi, Kübrich Marion, Pehlivanli Sinan, Meiser Bruno, Reichart Bruno, von Scheidt Wolfgang, Weis Michael
Medizinische Klinik und Poliklinik I, University Medical Center, Munich-Grosshadern, Germany.
Circulation. 2004 Sep 14;110(11 Suppl 1):II207-12. doi: 10.1161/01.CIR.0000138393.99310.1c.
Cardiac allograft vasculopathy (CAV) is initiated by allograft endothelial injury. We hypothesized that a major mechanism by which cytomegalovirus (CMV) could contribute to CAV is by dysregulation of the endothelial vasomotor response.
Coronary endothelial vasomotor function was determined in 183 consecutive patients (24+/-33 months after transplantation), and was correlated with recipient and donor CMV serological status before transplantation and with documented CMV infection episodes (CMVpp65Ag+). Serial endothelial function measurements were performed in a subgroup of 53 transplant recipients (1 month and 12 months after transplantation). The composite endpoint of cardiovascular related events and death during a follow-up of 66+/-41 months was analyzed based on the CMV serological status before transplantation.
The medium event-free time for CMV-negative recipients of CMV-positive hearts was 8.1 years compared with 13.3 years for the other groups (P<0.05). Distal epicardial but not microvascular endothelial function was significantly impaired in CMV seronegative recipients of seropositive donor hearts (n=48) compared with all other groups (P<0.01 versus seronegative recipient/seronegative donor; P<0.05 versus seropositive recipient/seronegative donor; P<0.05 versus seropositive recipient/seropositive donor). Distal epicardial endothelial dysfunction was more pronounced in heart transplant recipients with a history of documented CMV infection compared with patients without any documented CMV infection (P<0.01). In a longitudinal subgroup analysis, distal epicardial and microcirculatory endothelial vasomotor response deteriorated significantly in recipients with documented CMV infection (P<0.05 versus baseline) but not in patients without previous CMV infection.
Documented CMV infection episodes in heart transplant recipients are associated with impaired coronary endothelial function. CMV-negative recipients of CMV-positive donor hearts have an impaired distal epicardial endothelial function and an increased incidence of cardiovascular-related events and death during follow-up. CMV infection may contribute to allograft failure by accelerating coronary endothelial dysfunction.
心脏移植血管病变(CAV)由移植血管内皮损伤引发。我们推测巨细胞病毒(CMV)导致CAV的一个主要机制是内皮血管舒缩反应失调。
对183例连续患者(移植后24±33个月)的冠状动脉内皮血管舒缩功能进行测定,并与移植前受者和供者的CMV血清学状态以及记录的CMV感染发作(CMV pp65Ag阳性)相关联。对53例移植受者亚组(移植后1个月和12个月)进行内皮功能的系列测量。基于移植前的CMV血清学状态,分析了66±41个月随访期间心血管相关事件和死亡的复合终点。
CMV阳性心脏的CMV阴性受者的无事件中位时间为8.1年,而其他组为13.3年(P<0.05)。与所有其他组相比,CMV血清学阴性的血清学阳性供者心脏受者(n = 48)的远端心外膜而非微血管内皮功能明显受损(与血清学阴性受者/血清学阴性供者相比,P<0.01;与血清学阳性受者/血清学阴性供者相比,P<0.05;与血清学阳性受者/血清学阳性供者相比,P<0.05)。与无任何记录的CMV感染的患者相比,有记录的CMV感染史的心脏移植受者的远端心外膜内皮功能障碍更明显(P<0.01)。在纵向亚组分析中,有记录的CMV感染的受者的远端心外膜和微循环内皮血管舒缩反应明显恶化(与基线相比,P<0.05),而无既往CMV感染的患者则没有。
心脏移植受者有记录的CMV感染发作与冠状动脉内皮功能受损有关。CMV阳性供者心脏的CMV阴性受者的远端心外膜内皮功能受损,随访期间心血管相关事件和死亡的发生率增加。CMV感染可能通过加速冠状动脉内皮功能障碍导致移植失败。